Table 1 Characteristics of the primary and external test datasets
Primary dataset | External test dataset | Entire dataset | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
No. of subjects | Sex | Age in years (range) | No. of subjects | Sex | Age in years (range) | |||||
Male | Female | Male | Female | |||||||
Total | 7,900 | 5,380 (68%) | 2,520 (32%) | 45 ± 16 (2–86) | 1,819 | 1,228 (68%) | 591 (32%) | 47 ± 16 (1–88) | 9,719 | |
Normal control cohort | 1,250 | 700 (56%) | 550 (44%) | 37 ± 14 (10–78) | 403 | 230 (57%) | 173 (43%) | 41 ± 16 (6–79) | 1,653 | |
CVD cohort | 6,650 | 4,680 (70%) | 1,970 (30%) | 47 ± 15 (2–86) | 1,416 | 998 (71%) | 418 (29%) | 48 ± 16 (1–88) | 8,066 | |
1 | HCM | 2,327 | 1,513 (65%) | 814 (35%) | 48 ± 14 (7–86) | 388 | 260 (67%) | 128 (33%) | 51 ± 15 (9–86) | 2,715 |
2 | DCM | 1,435 | 1,076 (75%) | 359 (25%) | 44 ± 15 (4–82) | 204 | 140 (69%) | 64 (31%) | 50 ± 14 (8–76) | 1,639 |
3 | CAD | 942 | 829 (88%) | 113 (12%) | 56 ± 11 (8–83) | 299 | 269 (90%) | 30 (10%) | 56 ± 11 (24–88) | 1,241 |
4 | LVNC | 291 | 192 (66%) | 99 (34%) | 39 ± 16 (6–77) | 30 | 18 (60%) | 12 (40%) | 40 ± 14 (11–65) | 321 |
5 | RCM | 355 | 170 (48%) | 185 (52%) | 50 ± 20 (7–85) | 22 | 13 (59%) | 9 (41%) | 38 ± 24 (1–78) | 377 |
6 | CAM | 220 | 156 (71%) | 64 (29%) | 56 ± 11 (18–83) | 138 | 92 (67%) | 46 (33%) | 59 ± 9 (29–82) | 358 |
7 | HHD | 402 | 366 (91%) | 36 (9%) | 42 ± 13 (12–75) | 107 | 88 (82%) | 19 (18%) | 45 ± 14 (21–75) | 509 |
8 | Myocarditis | 87 | 64 (74%) | 23 (26%) | 28 ± 11 (14–69) | 66 | 48 (73%) | 18 (27%) | 26 ± 12 (8–68) | 153 |
9 | ARVC | 370 | 245 (66%) | 125 (34%) | 39 ± 14 (9–74) | 54 | 37 (68%) | 17 (32%) | 40 ± 14 (13–67) | 424 |
10 | PAH | 134 | 36 (27%) | 98 (73%) | 32 ± 12 (10–72) | 66 | 22 (33%) | 44 (67%) | 38 ± 17 (10–72) | 200 |
11 | Ebstein’s anomaly | 87 | 33 (38%) | 54 (62%) | 34 ± 16 (2–63) | 42 | 11 (26%) | 31 (74%) | 32 ± 14 (6–61) | 129 |
